Main Session
Sep 29
QP 34 - Skin and Sarcoma Shorts: Clinical Highlights and Recent Advances

1201 - Regional Control with Radiation Therapy Alone in Patients with Merkel Cell Carcinoma and Positive Sentinel Lymph Node Biopsy without Completion Dissection

05:25pm - 05:30pm ET
Room 210

Presenter(s)

Sayeh Fattahi, MD Headshot
Sayeh Fattahi, MD - Harvard Radiation Oncology Program, Boston, MA

S. Fattahi1, K. Y. Shin2, K. Melvin3,4, J. D. Schoenfeld3,4, R. B. Tishler3,4, I. M. Pashtan3,4, K. X. Liu3,4, C. Yoon5, D. Annino6, L. Goguen6, E. M. Rettig6, R. Sethi6, R. Uppaluri6, J. V. Cohen7, K. Khaddour7, A. W. Silk7, M. Thakuria8, and D. N. Margalit3,4; 1Harvard Radiation Oncology Program, Boston, MA, 2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, 3Department of Radiation Oncology, Brigham and Women’s Hospital, Boston, MA, 4Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, 5Department of Surgical Oncology, Brigham and Women's Hospital, Boston, MA, 6Department of Otolaryngology, Brigham and Women’s Hospital, Boston, MA, 7Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 8Department of Dermatology, Brigham and Women's Hospital, Boston, MA

Purpose/Objective(s): Merkel cell carcinoma (MCC) is a rare cutaneous tumor with a propensity for early regional lymph node involvement. Standard of care for clinically node-negative patients is a sentinel lymph node biopsy (SLNB), which detects occult nodal disease in approximately one-third of patients. Management of patients with positive SLNB is either completion lymph node dissection (CLND) typically followed by adjuvant RT, or radiation therapy (RT) alone to draining nodal basins. We hypothesized that for patients with positive SLNB treated with RT alone rather than CLND, nodal regional control is high.

Materials/Methods: This IRB-approved retrospective review identified patients with stage I-III MCC and a positive SLNB treated with RT without CLND at a single institution between 2005 and 2025. Patients with unknown primary were also included if they had an excisional lymph node biopsy and no other radiographically visible disease. All RT plans were reviewed for detailed patterns of failure analysis. Cumulative incidence of regional recurrence was calculated using Fine and Gray methods with competing risk of other recurrence type. Associations between regional recurrence and clinical factors (tumor location and immunosuppression status) were analyzed using multivariable competing risks regression.

Results: We identified 100 patients with positive SLNB who received RT without CLND, with a median dose of 50 Gy EQD2 to nodal basins. Patient characteristics included median age of 70.3 years (range, 45.3-89.5 years), 67% male, and 12% immunosuppressed. Primary tumor location was head and neck in 35% of patients, arm in 21%, leg in 19%, trunk in 13%, unknown in 9%, and buttock in 3%. Clinical stage was I in 48%, III in 32%, and II in 20%. At median follow-up of 5.0 years (range, 0.3-16.0 years), 4-year cumulative incidence of regional recurrence was 5.4% (95% confidence interval (CI): 2.0, 11.5%). There was no significant association between immunosuppression status and nodal regional recurrence. There was a significant association between tumor location of leg and unknown primary with nodal regional recurrence (p < 0.01 for both), but event rates were low, limiting power.

Conclusion: RT alone for patients with positive SLNB results in high rates of nodal regional control, supporting its role as an alternative approach to completion lymph node dissection.